World Journal of Urology

, Volume 15, Issue 2, pp 144–151 | Cite as

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation

  • U. Jonas
  • K. Höfner
  • H. Madersbacher
  • T. H. Holmdahl
  • participants of the international study group
Free Paper

Summary

Tolterodine is a new competitive muscarinic receptor antagonist developed for the treatment of the unstable bladder. A total of 242 patients were enrolled in a multicenter, multinational, randomized, double-blind, placebo-controlled study conducted over a period of 4 weeks in patients with detrusor overactivity and symptoms of frequency, urgency, and urge incontinence. The objective of the study was to compare the efficacy and safety of tolterodine given at 1 or 2 mg b.i.d. versus placebo. At week 4 a statistically significant increase in the volume at first contraction (p = 0.030) and maximal cystometric capacity (p = 0.034) was only in the tolterodine 2 mg b.i.d. group. Tolterodine was safe and generally well tolerated. The incidence of dry mouth, as the most commonly reported adverse event, was only 9% and of mild to moderate intensity.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35: 477–494Google Scholar
  2. 2.
    Couillard DR, Webster GD (1995) Detrusor instability. Urol Clin North Am 22: 593–612Google Scholar
  3. 3.
    Kelleher CI, et al (1994) Antichoinergic therapy: the need for continued surveillance (abstract 59). Neurol Urdoyn 13: 4Google Scholar
  4. 4.
    Lockhart JL, Shessel F, Weinstein D, Politano VA (1982) Urodynamics in women with stress and urge incontinence. Urology 20: 333–336Google Scholar
  5. 5.
    Nilvebrant L, et al (1997) Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci (in press)Google Scholar
  6. 6.
    Ouslander et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140: 47–50Google Scholar
  7. 7.
    Thüroff J, et al (1991) Randomised, double-blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–817Google Scholar
  8. 8.
    Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243–262Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • U. Jonas
    • 1
  • K. Höfner
    • 1
  • H. Madersbacher
    • 2
  • T. H. Holmdahl
    • 3
  • participants of the international study group
  1. 1.Department of UrologyHannover Medical SchoolHannoverGermany
  2. 2.University HospitalInnsbruckAustria
  3. 3.Länssjukhuset KvinnoklinikenKalmarSweden

Personalised recommendations